SGX943
Poster
Host-Directed Innate Defense Regulators with Preclinical and Clinical Proof of Concept
Donini O, Straube R. Host-Directed Innate Defense Regulators with Preclinical and Clinical Proof of Concept. Poster presentated at the 2018 American Society of Microbiology Microbe Conference. 2018.
Poster
Innate Defense Regulators (IDRs) – Agnostic Therapy to Treat Bacterial Infections and Fight Resistance
Donini O, Straube R. Host-Directed Innate Defense Regulators (IDRs) – Agnostic Therapy to Treat Bacterial Infections and Fight Resistance. Poster presentated at the 2018 ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. 2018.
Presentation
Modulation of Innate Immunity in the Treatment of Inflammation-Driven and Infection-Driven Disease
Donini O. Modulation of Innate Immunity in the Treatment of Inflammation-Driven and Infection-Driven Disease. Presentation at the 2017 Drug Discovery and Therapy World Congress Meeting. July 10-13, 2017.
Paper
Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients
Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Scott Z, Elder J, Sonis ST, Straube R, Donini O. Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. Biotech Reports. 2017; 15:24-26.
Presentation
Innate Defense Regulators: Agnostic Therapy for Antibiotic Resistant Disease-Supercharging existing and new antibiotic therapies
Donini O. Innate Defense Regulators: Agnostic Therapy for Antibiotic Resistant Disease – “Supercharging existing and new antibiotic therapies”. Presentation at the 2017 Superbugs & Superdrugs Meeting. March 20-21, 2017.
Paper
Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study
Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Elder J, Sonis S, Straube S, Donini O. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotech 2016; 239: 115-125.
Presentation
Dusquetide: Innate Defense Regulation as a Novel Approach to Antibiotic-Resistant Infection
Donini, O. Dusquetide: Innate Defense Regulation as a Novel Approach to Antibiotic-Resistant Infection. Presentation at BARDA TechWatch Meeting. August 2016.
Presentation
SGX942 Reduces the Duration of Severe Oral Mucositis
Donini O, Straube R. SGX942 Reduces the Duration of Severe Oral Mucositis. Presentation at 2016 Multinational Association for Supportive Care in Cancer Conference. June 23-25, 2016
Poster
An Innate Defense Regulator for the Treatment of Macrophage Activation Syndrome: Preclinical Studies in an Orphan Indication
Donini O, Behrens E, Haulenbeek A, Pullion C, Schaber C. An Innate Defense Regulator for the Treatment of Macrophage Activation Syndrome: Preclinical Studies in an Orphan Indication. Poster Presentated at the National Organization for Rare Diseases (NORD) Rare Diseases and Orphan Products Breakthrough Summit. 2016.
Poster
SGX942 REDUCES THE DURATION OF SEVERE ORAL MUCOSITIS
Donini O, Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Elder J. SGX942 Reduces the Duration of Severe Oral Mucositis. Poster presented at the 25th Multinational Association of Supportive Care in Cancer. 2016.